The pharmaceutical company and the digital therapeutics specialist are joining forces to help accelerate the expansion of various digital health solutions.
The drug company has renewed its arrangement with the artificial intelligence specialist, centered on using AI to improve understanding of the immune system.
Integrated research organization Circuit Clinical will standardize its decentralized operations with Medidata’s RAVE and myMedidata technological offerings.
The pharma firm has allied with the biotech to create a scalable data, analytics, and infrastructure platform to generate insights from healthcare biobanks.
The two companies, along with Datavant, will combine real-world data and decentralized platforms to yield better patient information management and insights.
The drug discovery firm will work with the Dean Felsher Laboratory, using the company’s transomics platform to discover therapies for untreatable cancers.
This month’s announcements include hiring, expansion, and acquisition news from companies like DFE Pharma, ClinOne, Novartis, LEGO, Benchling, and more.
Experts from the clinical tech firm talk data challenges and how monitoring technology can enable sites and sponsors to better manage audit trail reviews.
Medable has added Cognizant to its Medable Partner Network, designed to help companies launch their clinical trials more quickly and run them more efficiently.
The company (which specializes in developing therapies for rare cancers) currently is working on a number of candidates, including its lead drug CPI-613.
The recent Outsourcing-Pharma webinar hosted a trio of industry experts highlighting challenges, opportunities, and innovations in the rare disease realm.
With a specific focus on clinical trials involving treatments for rare diseases, Orphan Reach seeks to build upon the services that conventional CROs offer.
Ergomed, a global contract research organization, is partnering with Trialbee to improve patient recruitment at its new Rare Disease Innovation Center.
The AI-centered genomics company is joining with Don’t Forget Morgan, a group for patients with BPAN, to explore treatments for the neurodegenerative condition.
The pharmaceutical company’s Lilly Institute for Genetic Medicine reportedly will focus on developing RNA-based therapeutics in a ‘state-of-the-art’ facility.
In its latest diversity, equity and inclusion report, Global Genes offers insight into obstacles faced by rare-disease patients from minority communities.
A representative from the HIV-centered pharmaceutical company shares thoughts and perspective on the every-two-month treatment and how it might help patients.
The agency has given the go-ahead for a Phase I study of the company’s IO-202 antibody (in combination with Merck’s Keytruda) to treat various tumor types.
The two companies, which have been collaborating for 15 years, reportedly will focus on elevating decentralized trial solutions to develop new therapies.
The CRO is helping out on a project exploring the effects of the virus in children; other members of the research team include experts from Duke University.
On February 23, five days ahead of the day of rare-disease awareness, OSP’s Rare and Orphan Diseases webinar will share insights from top industry experts.
Created via a joint effort with EY, the pharmaceutical company launched ASPIREs, a program intended to improve its clinical trial processes in numerous areas.
In its forward-looking report on digital health, the consulting outfit offers predictions on what changes are ahead and how they might impact the field.
This month’s list of announcements about technology, funding, and more includes Medable, Clarify Health, Thermo Fisher Scientific, and other key companies.
The institute and the research/support organization will collaborate on development of novel therapies aimed at treating the central nervous system disorder.
According to a representative from the decentralized trial solutions company, the field of digital therapeutics is poised to gain significant popularity.
An expert from the institutional review board services company advises what trends to look for in the clinical trial industry over the course of coming months.
Cullinan Oncology has formed a strategic partnership with the Icahn School of Medicine at Mount Sinai to research and develop targeted therapies for cancer.
In this second of a two-part series, experts from the clinical research organization share thoughts on how data management technology, personnel, and partnerships have evolved.
In the first of a two-part series, leaders from the CRO discuss how study data has progressed in recent years and how trial teams can keep up effectively.
The pharmaceutical company, which uses thin-film freezing to develop inhalable therapies, has completed enrollment in the first phase for its drug candidate.
The company’s analysis of trials conducted around the world last year shows cancers took four of the top five positions, with COVID-19 in second place.
Vision, part of the company’s Clinical Maestro platform of software-as-a-solution applications, enables study teams to manage clinical vendor oversight.
The latest in the Diversity in Oncology series, taking place February 9, will discuss ways academia and community collaboration can narrow representation gaps.
The precision medicine company is joining with decentralized trial specialist Curebase to bring its cancer studies to a more diverse group of patients.
An expert from the CRO discusses the role real-world data plays in developing therapies, with benefits ranging from speeding recruitment to decreasing costs.
The collaboration between the trial tech company and heathcare firm is aimed at increasing study access at MinuteClinic locations using Medable’s software.
A leader from the artificial intelligence insights specialist talks discusses how the effective use of advanced analytics can lead to a number of benefits.
During OSP’s exclusive February 23 webinar Rare and Orphan Diseases, leading expertswill lend their unique experience and expertise to the important topic.
The Stoneygate and Kidney Research UK Alport Research Hub aims to accelerate research and develop treatments for Alport syndrome, a rare genetic disorder.
Biogen releases further details on how its Phase 4 post-marketing confirmatory study for Alzheimer’s drug, Aduhelm, will run: including increased enrolment and enhanced efforts to encourage diversity.
The pharma firm has announced the agency has approved the company’s investigational new drug application for its Phase II trial of pemvidutide for obesity.
In a partnership with Medable, a center at the university discovered costs linked to investing in decentralized studies far outweigh the eventual benefits.
A representative from IQVIA discusses the particulars of the US agency’s new draft document and shares what it might mean for clinical trial data evaluation.
A leader from Elligo Health Research (a SCOPE 2022 exhibitor ) discusses flaws in traditional recruitment approaches and offers up some fresh new ideas.
A leader from the RBQM solutions specialists offers a preview of his SCOPE 2022 presentation on tools suited to decentralized trial design and management.
The upcoming industry event offers attendees (in-person and virtual) a range of opportunities to learn, connect, and innovate, according to an organizer.
One of the finalists for the 2022 Participant Engagement Award (saluting patient recruitment and retention solution) will be announced as winner at SCOPE.
An expert from the CRO discusses unique challenges associated with running clinical trials that stretch across national boarders and how to conquer them.
